Request for Applications (RFAs)


Unmeeting Logo Un-Meeting RFAs

An Un-Meeting is a collaborative event without the rules and structure of a traditional conference.

Learn more

Synergy Logo Synergy Paper RFAs

Cross-network translational research “synergy” papers are designed to focus on significant challenges in clinical and translational research.

Learn more

Consortium RFAs

Clinical Trial for a Rare Disease or Condition Credit: Vince Sullivan, University of Rochester
Notice of Intent to Support a Phase III Clinical Trial for a Rare Disease or Condition


Pursuant to the "NCATS Policy for Support of Phase III Clinical Trial Activities for a Rare Disease or Condition", NCATS is providing this public notice period and opportunity for any public or private organization to submit a reply on the contemplation of NCATS to support a Phase III clinical trial activity for a rare disease or condition (as defined here(link is external)). Specifically, NCATS seeks responses from any public or private organization with credible, timely plans to conduct Phase III clinical trials of a similar nature. Respondents must provide sufficient information to enable an accurate determination of whether the respondents’ clinical trial activities are timely and of a similar nature to the trial described below.

NCATS intends to support the following Phase III Clinical Trial(s) for a Rare Disease or Condition:

  • "STeroids to REduce Systemic Inflammation After Neonatal Heart Surgery (STRESS),” details of which can be found at NCT03229538(link is external). (Posted on May 24, 2019).

Responses should include a credible, timely plan and contact information. Please direct all inquiries to: NCATS Policy Officer:

May 29, 2019

Twitter logoFollow CLIC
Twitter logoFollow NCATS